FY2018 Earnings Forecast for Agile Therapeutics Inc (AGRX) Issued By William Blair

Agile Therapeutics Inc (NASDAQ:AGRX) – Research analysts at William Blair decreased their FY2018 EPS estimates for shares of Agile Therapeutics in a research note issued on Monday, November 5th. William Blair analyst T. Lugo now expects that the specialty pharmaceutical company will post earnings of ($0.57) per share for the year, down from their prior estimate of ($0.56). William Blair also issued estimates for Agile Therapeutics’ Q4 2018 earnings at ($0.09) EPS and FY2019 earnings at ($0.42) EPS.

Agile Therapeutics (NASDAQ:AGRX) last issued its quarterly earnings results on Thursday, November 1st. The specialty pharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.04.

Several other equities analysts have also issued reports on AGRX. ValuEngine upgraded Agile Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, August 3rd. HC Wainwright set a $4.00 price target on Agile Therapeutics and gave the company a “buy” rating in a research note on Tuesday, October 9th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Agile Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $4.00.

Shares of AGRX opened at $0.96 on Thursday. Agile Therapeutics has a 52-week low of $0.23 and a 52-week high of $5.33. The firm has a market capitalization of $33.08 million, a PE ratio of -1.05 and a beta of -0.95.

Several institutional investors and hedge funds have recently modified their holdings of AGRX. Dimensional Fund Advisors LP increased its stake in shares of Agile Therapeutics by 62.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 145,070 shares of the specialty pharmaceutical company’s stock valued at $373,000 after purchasing an additional 55,937 shares during the last quarter. A.R.T. Advisors LLC increased its stake in shares of Agile Therapeutics by 82.3% in the 1st quarter. A.R.T. Advisors LLC now owns 66,426 shares of the specialty pharmaceutical company’s stock valued at $170,000 after purchasing an additional 29,995 shares during the last quarter. Finally, Renaissance Technologies LLC increased its stake in shares of Agile Therapeutics by 76.3% in the 2nd quarter. Renaissance Technologies LLC now owns 792,990 shares of the specialty pharmaceutical company’s stock valued at $392,000 after purchasing an additional 343,290 shares during the last quarter. Institutional investors own 51.92% of the company’s stock.

About Agile Therapeutics

Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials.

Recommended Story: What are the reasons investors use put options?

Earnings History and Estimates for Agile Therapeutics (NASDAQ:AGRX)

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply